Research programme: antiviral therapeutics - Assembly Biosciences
Latest Information Update: 27 Jan 2022
At a glance
- Originator Assembly Biosciences
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Viral infections
Most Recent Events
- 27 Jan 2022 Research programme: antiviral therapeutics - Assembly Biosciences is available for licensing as of 27 Jan 2022. https://www.assemblybio.com/collaborations/
- 27 Jan 2022 Early research in Viral infections in USA (unspecified route) (Assembly Biosciences pipeline, January 2022)